ReproCELL Incorporated
AMED Subsidy Grant Decision Notice for the Public Offering Project: Infrastructure Development for Industrialization of Regenerative Medicine and Gene Therapy (Task: Development of Manufacturing Process for Tumor-Infiltrating Lymphocytes (TIL) Regenerative Medicine Products for Advanced Cervical Cancer)
Received notice of the subsidy grant decision related to the AMED public offering project. Project period: 2026/9/14 to 2027/3/31. Estimated grant amount for fiscal year 2026 is 79,993 thousand yen; final amount will be confirmed by AMED's notification. No impact on consolidated results for the fiscal year ending March 2027.
Key Figures
- Public offering project period: September 14, 2026 to March 31, 2027
- Fiscal year 2026 grant amount (estimated): 79,993 thousand yen
- Final grant amount confirmation by AMED final notification
AI要約
Performance / Subsidy Overview
This notice informs that the proposal related to the AMED public offering project has been selected and the grant decision notice has been received. The public offering project period is from September 14, 2026 to March 31, 2027, and the estimated grant amount for fiscal year 2026 is 79,993 thousand yen. The final grant amount and the timing of recognition will be determined by AMED's final notification.
Impact and Financial Outlook Going Forward
Official grant amount confirmation is expected next year, and will be announced promptly once determined. It is explicitly stated that there is no expected impact on the consolidated results for the fiscal year ending March 2027. While research and development funding is expected to strengthen the research framework, the direct financial impact on earnings is considered limited.
ReproCELL Incorporated
Company overview · Stock price · Financial data · All IR
